1 |
Tai C, Goldenberg M, Schuster KM, et al. Composite tissue allotransplantation. J Invest Surg 2003;16:193-201.
DOI
|
2 |
Cendales LC, Xu H, Bacher J, et al. Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. Transplantation 2005;80:1447-54.
DOI
|
3 |
Dubernard JM, Owen E, Herzberg G, et al. Human hand allograft: report on first 6 months. Lancet 1999;353:1315-20.
DOI
|
4 |
Petit F, Minns AB, Dubernard JM, et al. Composite tissue allotransplantation and reconstructive surgery: first clinical applications. Ann Surg 2003;237:19-25.
DOI
|
5 |
Devauchelle B, Badet L, Lengele B, et al. First human face allograft: early report. Lancet 2006;368:203-9.
DOI
|
6 |
Lanzetta M, Petruzzo P, Margreiter R, et al. The International Registry on Hand and Composite Tissue Transplantation. Transplantation 2005;79:1210-4.
DOI
|
7 |
Lechler RI, Sykes M, Thomson AW, et al. Organ transplantation-- how much of the promise has been realized? Nat Med 2005;11:605-13.
DOI
|
8 |
Calne RY. Prope tolerance: the future of organ transplantation from the laboratory to the clinic. Int Immunopharmacol 2005;5:163-7.
DOI
|
9 |
Siemionow M, Klimczak A. Basics of immune responses in transplantation in preparation for application of composite tissue allografts in plastic and reconstructive surgery: part I. Plast Reconstr Surg 2008;121:4e-12e.
DOI
|
10 |
Womer KL, Stone JR, Murphy B, et al. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol 2001;12:2500-6.
|
11 |
Womer KL, Sayegh MH, Auchincloss H Jr. Involvement of the direct and indirect pathways of allorecognition in tolerance induction. Philos Trans R Soc Lond B Biol Sci 2001; 356:639-47.
DOI
|
12 |
Ensminger SM, Spriewald BM, Witzke O, et al. Indirect allorecognition can play an important role in the development of transplant arteriosclerosis. Transplantation 2002;73:279-86.
DOI
|
13 |
Lee RS, Yamada K, Houser SL, et al. Indirect allorecognition promotes the development of cardiac allograft vasculopathy. Transplant Proc 2001;33:308-10.
DOI
|
14 |
Rogers NJ, Lechler RI. Allorecognition. Am J Transplant 2001;1:97-102.
DOI
|
15 |
Cendales LC, Kirk AD, Moresi JM, et al. Composite tissue allotransplantation: classification of clinical acute skin rejection. Transplantation 2005;80:1676-80.
|
16 |
Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004;4:1562-6.
DOI
|
17 |
Lee WP, Yaremchuk MJ, Pan YC, et al. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg 1991;87:401-11.
DOI
|
18 |
Buttemeyer R, Jones NF, Min Z, et al. Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine. Plast Reconstr Surg 1996; 97:139-48.
DOI
|
19 |
Rocha PN, Plumb TJ, Crowley SD, et al. Effector mechanisms in transplant rejection. Immunol Rev 2003;196:51-64.
DOI
|
20 |
Aw MM. Transplant immunology. J Pediatr Surg 2003;38: 1275-80.
DOI
|
21 |
Hancock WW, Gao W, Shemmeri N, et al. Immunopathogenesis of accelerated allograft rejection in sensitized recipients: humoral and nonhumoral mechanisms. Transplantation 2002;73:1392-7.
DOI
|
22 |
Monaco AP. Prospects and strategies for clinical tolerance. Transplant Proc 2004;36:227-31.
DOI
|
23 |
Kanitakis J, Jullien D, Petruzzo P, et al. Clinicopathologic features of graft rejection of the first human hand allograft. Transplantation 2003;76:688-93.
DOI
|
24 |
Petruzzo P, Badet L, Gazarian A, et al. Bilateral hand transplantation: six years after the first case. Am J Transplant 2006;6:1718-24.
DOI
|
25 |
Williams JM, Holzknecht ZE, Plummer TB, et al. Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation. Transplantation 2004;78:1471-8.
DOI
|
26 |
Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant 2005;5:2611-8.
DOI
|
27 |
Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol 2000;20:126-47.
|
28 |
Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995;59:313-8.
DOI
|
29 |
Joosten SA, Sijpkens YW, van Kooten C, et al. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int 2005;68:1-13.
DOI
|
30 |
Womer KL, Lee RS, Madsen JC, et al. Tolerance and chronic rejection. Philos Trans R Soc Lond B Biol Sci 2001;356: 727-38.
DOI
|
31 |
Takada M, Nadeau KC, Hancock WW, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 1998;65:1533-42.
DOI
|
32 |
Ozer K, Oke R, Gurunluoglu R, et al. Induction of tolerance to hind limb allografts in rats receiving cyclosporine A and antilymphocyte serum: effect of duration of the treatment. Transplantation 2003;75:31-6.
DOI
|
33 |
Singer P, Shapiro H, Cohen J. Brain death and organ damage: the modulating effects of nutrition. Transplantation 2005;80:1363-8.
DOI
|
34 |
Kuecuek O, Mantouvalou L, Klemz R, et al. Significant reduction of proinflammatory cytokines by treatment of the brain-dead donor. Transplant Proc 2005;37:387-8.
DOI
|
35 |
Takada M, Nadeau KC, Shaw GD, et al. The cytokineadhesion molecule cascade in ischemia/reperfusion injury of the rat kidney: inhibition by a soluble P-selectin ligand. J Clin Invest 1997;99:2682-90.
DOI
|
36 |
Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52- specific monoclonal antibody alemtuzumab (CAMPATH- 1H). Transplantation 2003;76:120-9.
DOI
|
37 |
Siemionow M, Klimczak A. Tolerance and future directions for composite tissue allograft transplants: part II. Plast Reconstr Surg 2009;123:7e-17e.
DOI
|
38 |
Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: recent developments in molecular action and clinical application. Transplant Proc 1998;30:1573-9.
DOI
|
39 |
Gorantla VS, Barker JH, Jones JW Jr, et al. Immunosuppressive agents in transplantation: mechanisms of action and current anti-rejection strategies. Microsurgery 2000;20:420-9.
DOI
|
40 |
Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
DOI
|
41 |
Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001; 59:3-16.
DOI
|
42 |
Engl T, Makarevic J, Relja B, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 2005;5:4.
DOI
|
43 |
Goggins WC, Fisher RA, Dattilo JB, et al. Analysis of functional renal allograft tolerance with single-dose rapamycin based induction immunosuppression. Transplantation 1997; 63:310-4.
DOI
|
44 |
Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005;80:S254-64.
DOI
|
45 |
Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005;200:505-15.
DOI
|
46 |
Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003;76:1289-93.
DOI
|
47 |
Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361:1502-10.
DOI
|
48 |
Jones NF. Concerns about human hand transplantation in the 21st century. J Hand Surg Am 2002;27:771-87.
DOI
|
49 |
Thaunat O, Badet L, El-Jaafari A, et al. Composite tissue allograft extends a helping hand to transplant immunologists. Am J Transplant 2006;6:2238-42.
DOI
|
50 |
Petruzzo P, Revillard JP, Kanitakis J, et al. First human double hand transplantation: efficacy of a conventional immunosuppressive protocol. Clin Transplant 2003;17:455-60.
DOI
|
51 |
Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998;338:1813-21.
DOI
|
52 |
Noel PJ, Boise LH, Green JM, et al. CD28 costimulation prevents cell death during primary T cell activation. J Immunol 1996;157:636-42.
|
53 |
Wood K, Sachs DH. Chimerism and transplantation tolerance: cause and effect. Immunol Today 1996;17:584-7.
DOI
|
54 |
Zheng XX, Sanchez-Fueyo A, Domenig C, et al. The balance of deletion and regulation in allograft tolerance. Immunol Rev 2003;196:75-84.
DOI
|
55 |
Papiernik M, de Moraes ML, Pontoux C, et al. Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 1998; 10:371-8.
DOI
|
56 |
Larsen CP, Knechtle SJ, Adams A, et al. A new look at blockade of T-cell costimulation: a therapeutic strategy for longterm maintenance immunosuppression. Am J Transplant 2006;6:876-83.
DOI
|
57 |
Sachs DH. Mixed chimerism as an approach to transplantation tolerance. Clin Immunol 2000;95:S63-8.
DOI
|
58 |
Monaco AP. Antilymphocyte serum, donor bone marrow and tolerance to allografts: the journey is the reward. Transplant Proc 1999;31:67-71.
DOI
|
59 |
Wekerle T, Sykes M. Mixed chimerism and transplantation tolerance. Annu Rev Med 2001;52:353-70.
DOI
|
60 |
Starzl TE, Demetris AJ, Trucco M, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1993;17:1127-52.
DOI
|
61 |
Starzl TE, Demetris AJ, Murase N, et al. The lost chord: microchimerism and allograft survival. Immunol Today 1996; 17:577-84.
DOI
|
62 |
Starzl TE, Demetris AJ. Transplantation tolerance, micro chimerism, and the two-way paradigm. Theor Med Bioeth 1998;19:441-55.
DOI
|
63 |
Kanitakis J, Jullien D, Claudy A, et al. Microchimerism in a human hand allograft. Lancet 1999;354:1820-1.
|
64 |
Yu X, Carpenter P, Anasetti C. Advances in transplantation tolerance. Lancet 2001;357:1959-63.
DOI
|
65 |
Sprent J, Kishimoto H. The thymus and negative selection. Immunol Rev 2002;185:126-35.
DOI
|
66 |
Siemionow M, Ortak T, Izycki D, et al. Induction of tolerance in composite-tissue allografts. Transplantation 2002; 74:1211-7.
DOI
|
67 |
Jonuleit H, Schmitt E, Kakirman H, et al. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 2002;196:255-60.
DOI
|
68 |
Raulet DH, Vance RE. Self-tolerance of natural killer cells. Nat Rev Immunol 2006;6:520-31.
DOI
|
69 |
Kyewski B, Derbinski J. Self-representation in the thymus: an extended view. Nat Rev Immunol 2004;4:688-98.
DOI
|
70 |
Anderson G, Partington KM, Jenkinson EJ. Differential effects of peptide diversity and stromal cell type in positive and negative selection in the thymus. J Immunol 1998; 161:6599-603.
|
71 |
Li L, Boussiotis VA. Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. J Mol Med (Berl) 2006;84:887-99.
DOI
|
72 |
Siemionow M, Izycki D, Ozer K, et al. Role of thymus in operational tolerance induction in limb allograft transplant model. Transplantation 2006;81:1568-76.
DOI
|
73 |
Belz GT, Behrens GM, Smith CM, et al. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002;196: 1099-104.
DOI
|
74 |
Coulson MT, Jablonski P, Howden BO, et al. Beyond operational tolerance: effect of ischemic injury on development of chronic damage in renal grafts. Transplantation 2005;80: 353-61.
DOI
|
75 |
Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998;351:1701-2.
|
76 |
Belz GT, Heath WR, Carbone FR. The role of dendritic cell subsets in selection between tolerance and immunity. Immunol Cell Biol 2002;80:463-8.
DOI
|
77 |
Zhong R, Tucker J, Grant D, et al. Long-term survival and functional tolerance of baboon to monkey kidney and liver transplantation: a preliminary report. Transplant Proc 1996; 28:762.
|
78 |
Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007;7:309-19.
DOI
|
79 |
Grohmann U, Bianchi R, Orabona C, et al. Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J Immunol 2003;171:2581-7.
DOI
|
80 |
Adorini L, Giarratana N, Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 2004;16:127-34.
DOI
|
81 |
Taner T, Hackstein H, Wang Z, et al. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005;5:228-36.
DOI
|
82 |
Ciancio G, Miller J, Garcia-Morales RO, et al. Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation 2001;71:827-35.
DOI
|
83 |
Kreisel D, Petrowsky H, Krasinskas AM, et al. The role of passenger leukocyte genotype in rejection and acceptance of rat liver allografts. Transplantation 2002;73:1501-7.
DOI
|
84 |
Ko S, Deiwick A, Jager MD, et al. The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat. Nat Med 1999;5:1292-7.
DOI
|
85 |
Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-8.
DOI
|
86 |
Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
|
87 |
Jonuleit H, Adema G, Schmitt E. Immune regulation by regulatory T cells: implications for transplantation. Transpl Immunol 2003;11:267-76.
DOI
|